A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer

BACKGROUND: Eribulin is a microtubule dynamics inhibitor with a novel mechanism of action. This phase 3 study aimed to compare overall survival (OS) in patients with heavily pretreated non-small cell lung cancer (NSCLC) receiving eribulin to treatment of physician’s choice (TPC). PATIENTS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Katakami, N., Felip, E., Spigel, D. R., Kim, J.-H., Olivo, M., Guo, M., Nokihara, H., Yang, J. C.-H., Iannotti, N., Satouchi, M., Barlesi, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834051/
https://www.ncbi.nlm.nih.gov/pubmed/28911085
http://dx.doi.org/10.1093/annonc/mdx284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834051/
https://www.ncbi.nlm.nih.gov/pubmed/28911085
http://dx.doi.org/10.1093/annonc/mdx284

Ejemplares similares